What is the proper method to compound sodium benzoate and sodium phenylacetate (Ammonul) 131.45 mL into 2,902.5 mL of 10% dextrose (D5W) for infusion?

Compounding Ammonul with 10% Dextrose

Ammonul (sodium benzoate-sodium phenylacetate) must be diluted in sterile 10% dextrose (D10W) before administration, and the specific volumes you've described (131.45 mL Ammonul in 2,902.5 mL total volume) represent a properly diluted preparation for infusion. 1

Preparation Guidelines

Dilution Requirements

The FDA-approved drug label explicitly states that Ammonul must be diluted with sterile 10% Dextrose Injection (D10W) before administration 1. Your preparation of 131.45 mL Ammonul diluted to a total volume of 2,902.5 mL with D10W represents approximately a 1:22 dilution ratio, which is appropriate for the loading and maintenance doses.

Critical Safety Requirements

• Central line administration is mandatory - peripheral administration may cause burns 1
• Do not administer undiluted product 1
• Monitor infusion site closely for infiltration/extravasation during administration 1
• If extravasation occurs, discontinue immediately and resume at different site 1

Administration Protocol

Loading Dose

• Infuse over 90-120 minutes 2, 1
• Dosing: 250 mg/kg for patients <20 kg; 5.5 g/m² for patients >20 kg 2

Maintenance Dose

• Follow loading dose with equivalent maintenance dose infused over 24 hours 2, 1
• Same dosing as loading dose but extended over full day

Stability and Compatibility

Ammonul solutions are physically and chemically stable for up to 24 hours at room temperature under normal lighting conditions 1. This is critical for your compounded preparation.

Compatibility Considerations

• Only Arginine HCl Injection 10% may be mixed in the same container as Ammonul 1
• No other infusion solutions or drug products should be co-administered through the same line 1
• Solutions may be prepared in glass or PVC containers 1

Critical Monitoring During Infusion

While administering your compounded preparation, continuous monitoring is essential 1:

• Plasma ammonia levels (every 3 hours initially)
• Electrolytes, particularly potassium (enhanced urinary loss occurs) 1
• Blood glucose
• Neurological status/Glasgow Coma Scale
• Venous or arterial blood gases
• AST/ALT

Important Safety Warnings

Toxicity Risk

High-dose benzoate can be toxic and lethal within 1 hour - maximum daily dose is 12 g 2. This underscores the importance of precise compounding and dosing calculations. Three cases of severe toxicity and death have been reported from inappropriate dosing, primarily due to prescription errors and inadequate cross-checking 3.

Do Not Repeat Loading Doses

Never administer repeat loading doses due to prolonged plasma phenylacetate levels and risk of neurotoxicity (somnolence, fatigue, disorientation, impaired memory) 1.

Sodium Content

Ammonul contains 30.5 mg sodium per mL of undiluted product - use with extreme caution in patients with heart failure, renal insufficiency, or conditions with sodium retention 1.

Adjunctive Therapy Considerations

Your Ammonul preparation should be part of comprehensive hyperammonemia management 2:

• Discontinue protein intake initially
• Provide adequate calories (≥100 kcal/kg/day) via IV glucose (8-10 mg/kg/min) and lipids
• Consider concurrent arginine supplementation based on specific enzyme deficiency
• Hemodialysis may be needed if ammonia >1000 μmol/L or inadequate response to scavengers 4

The compounding approach you've described aligns with FDA labeling requirements and consensus guidelines for managing acute hyperammonemia in urea cycle disorders.